Production (Stage)
Sarepta Therapeutics, Inc.
SRPT
$37.60
-$1.01-2.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,338.98% | 248.37% | 182.10% | 126.98% | 106.99% |
| Total Depreciation and Amortization | 14.11% | -8.06% | -10.27% | -19.21% | -22.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 218.41% | 23.13% | 46.41% | 172.74% | -89.96% |
| Change in Net Operating Assets | 14.51% | 16.83% | -40.02% | 3.51% | -155.40% |
| Cash from Operations | -141.01% | 268.41% | 38.37% | 112.22% | -15.61% |
| Capital Expenditure | -34.54% | -100.02% | -25.58% | -62.86% | -242.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -198.52% | 1,870.12% | 49.38% | -160.55% | 1,043.20% |
| Cash from Investing | -233.08% | 1,287.29% | 38.82% | -201.96% | 1,651.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -29.17% | 90.94% | -10.70% | 581.08% | -21.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -43.67% | 2,421.41% | -10.70% | 581.08% | -78.25% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -75,526.58% | 873.16% | 40.05% | -121.23% | 98.80% |